Skip to content
Peptidepedia

Melanotan II Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

MT-II with PT-141 (Bremelanotide)

Some users alternate between MT-II for tanning and PT-141 for sexual function enhancement, as PT-141 lacks significant tanning effects. PT-141 is FDA-approved for hypoactive sexual desire disorder in women, giving it a different legal and safety profile. See PT-141 vs Melanotan II for a full breakdown of the differences. These two peptides should not be used simultaneously due to overlapping receptor activity.

MT-II with Growth Hormone Secretagogues

Bodybuilders occasionally combine MT-II with ipamorelin or CJC-1295 for multiple cosmetic and body composition goals. No synergistic interaction between MT-II and growth hormone secretagogues has been established in research.

MT-II in Cutting Phases

Some users incorporate MT-II into cutting or body recomposition phases alongside other compounds, citing its mild appetite suppression. However, its contribution to fat loss as a standalone mechanism is considered modest and is not supported by dedicated human trials.

Frequently Asked Questions

Most users notice enhanced tanning within 2–3 weeks when combining MT-II with moderate UV exposure. Initial darkening may be subtle, with pronounced results developing over 4–6 weeks of consistent use.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Dorr RT, et al. Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences. 1996;58(20):1777-84.
  2. Wessells H, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. Journal of Urology. 1998;160(2):389-93.
  3. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-30.
  4. Fan W, et al. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature. 1997;385(6612):165-8.
  5. Brennan R, et al. Melanotan II: a review of the evidence for efficacy and safety. Dermatology Online Journal. 2019.
  6. U.S. Food and Drug Administration. Tainted Sexual Enhancement Products. FDA Consumer Updates.
  7. World Anti-Doping Agency. The 2024 Prohibited List. WADA.
  8. Hruby VJ, et al. Cyclic lactam alpha-melanotropin analogues with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors. Journal of Medicinal Chemistry. 1995;38(18):3454-61.
←Read the full Melanotan II guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”